Home Cart Sign in  
Chemical Structure| 1229236-86-5 Chemical Structure| 1229236-86-5

Structure of Gandotinib
CAS No.: 1229236-86-5

Chemical Structure| 1229236-86-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gandotinib (LY2784544) is a potent JAK2 inhibitor with an IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 values of 4, 25, 32, 44, and 95 nM, respectively.

Synonyms: LY2784544

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Gandotinib

CAS No. :1229236-86-5
Formula : C23H25ClFN7O
M.W : 469.94
SMILES Code : CC1=CC(NC2=NN3C(C(CN4CCOCC4)=C2)=NC(C)=C3CC5=CC=C(Cl)C=C5F)=NN1
Synonyms :
LY2784544
MDL No. :MFCD20482143
InChI Key :SQSZANZGUXWJEA-UHFFFAOYSA-N
Pubchem ID :46213929

Safety of Gandotinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Gandotinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK1

    JAK1, IC50:19.8 nM

  • JAK3

    JAK3, IC50:48.0 nM

  • Tyk2

    TYK2, IC50:44 nM

  • JAK2

    JAK2 (V617F), Ki:0.245 nM

    JAK2, IC50:0.288 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
COS7 cells 1 μM 48 h to elicit MISR2 signaling in cultured mouse ovaries PMC9169708
Trypanosoma brucei 0.6 μM 15 min To test the inhibitory effect of LY2784544 on Tf endocytosis, the results showed that LY2784544 at low micromolar concentrations prevented Tf endocytosis and trypanosome proliferation. PMC5025259
HMC-1.2 cells 2.65 µM 48 hours To evaluate the effect of JAK inhibitors on the viability of HMC-1.2 cells, it was found that fedratinib and gandotinib significantly reduced cell viability PMC11815366
ROSAKIT D816V cells 2.32 µM 48 hours To evaluate the effect of JAK inhibitors on the viability of ROSAKIT D816V cells, it was found that fedratinib and gandotinib significantly reduced cell viability PMC11815366

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Neonatal rat pups Intraperitoneal injection 20 mg/kg once per day for 10 d to test the bioactivity of candidate agonists and inhibit primordial follicle activation PMC9169708
Mice SKOV3 CR xenograft tumors Intraperitoneal injection 15 mg/kg/day 2 weeks To evaluate the therapeutic efficacy of LY2784544 in overcoming platinum resistance in ovarian cancer and its effects in combination with cisplatin. PMC6054535

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01134120 Myeloproliferative Disorders|T... More >>hrombocythemia, Essential|Polycythemia Vera|Primary Myelofibrosis Less << PHASE1 COMPLETED 2018-02-22 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, 77030, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, 84132, United States Less <<
NCT01577355 Healthy Male Volunteers Phase 1 Completed - United States, Wisconsin ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madison, Wisconsin, United States, 53704 Less <<
NCT01594723 Neoplasms, Hematologic Phase 2 Active, not recruiting December 31, 2019 -
NCT01520220 Myeloproliferative Neoplasms o... More >>f|Polycythemia Vera|Essential Thrombocythemia|Myelofibrosis Less << PHASE1 COMPLETED 2017-02-24 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, 35249, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, 85259, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, 72703, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, 20007, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, 32224, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, 96813, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, 29425, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, 84132, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, 53226, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.64mL

2.13mL

1.06mL

21.28mL

4.26mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories